Medicines Co. Settles Patent Suit With APP Over Generic Copy of Angiomax

Medicines Co. (MDCO) and Fresenius (FRE)’s APP Pharmaceuticals Inc. (APPX) settled litigation over patents for the Angiomax anticoagulant drug, with Medicines agreeing to pay $30 million to license some APP drugs.

Medicines Co., based in Parsippany, New Jersey, sued Schaumburg, Illinois-based APP in October 2009 IN Wilmington, Delaware, federal court alleging patent infringement for plans to market a generic copy of Angiomax. APP announced the settlement today.

“The settlement agreement includes a license by The Medicines Co. to APP” to sell generic Angiomax in the U.S. starting May 1, 2019, Medicines said in a statement.

Medicines will pay APP $30 million for a non-exclusive license “to sell 10 specified generic products” to hospitals and suppliers until Jan. 22, 2022, according to a Medicines filing with the U.S. Securities and Exchange Commission.

The case is The Medicines Co. v. APP Pharmaceuticals, 09- CV-00752, U.S. District Court, District of Delaware (Wilmington).

To contact the reporter on this story: Phil Milford in Wilmington, Delaware, at pmilford@bloomberg.net.

To contact the editor responsible for this story: Michael Hytha at mhytha@bloomberg.net.

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.